bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer).
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2010.
Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome.
High-tech Mobile Laboratory Brings Education and Training to Healthcare and Quality Assurance Professionals Across North America
bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology.
The award highlights the automated media streaker’s breakthrough technology.
Cost-effective chromogenic media ideal for VRE identification in hospitals and laboratories
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on Friday, March 5, 2010 to approve the consolidated financial statements for the year ended December 31, 2009. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors are in the process of issuing an unqualified opinion.
A powerful strategic vision for 2010-2015, driven by innovation and international development.
bioTheranostics, a bioMérieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
